An Exploratory, Single-Blind, Placebo-Controlled, Randomized, Single- and Multiple-Dose Pharmacodynamics Study in Healthy Subjects to Evaluate the Effect of JNJ-54175446 on Amyloid Biomarkers and Cytokine Profiles in Cerebrospinal Fluid and Plasma
Phase of Trial: Phase I
Latest Information Update: 19 Jan 2017
At a glance
- Drugs JNJ 54175446 (Primary)
- Indications Major depressive disorder
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Janssen Research & Development
- 13 Jan 2017 Status changed from recruiting to completed.
- 22 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Nov 2016.
- 22 Nov 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Nov 2016.